New High-Tech Collagen Assists in Closing Surgical Wounds

FORT WORTH, Texas, Oct. 1, 2012 /PRNewswire/ -- Wound Management Technologies, Inc. (OTCQB: WNDM | WNDM.PK), a Fort Worth, Texas healthcare company, announced today their first application of their new product CellerateRX Surgical. This product was used as the primary, full-thickness incision dressing for a surgical procedure performed by orthopedic surgeon Dr. Blaine Farless at a hospital in North Texas.

(Photo: http://photos.prnewswire.com/prnh/20121001/DA83944)

CellerateRX Surgical is a patented, hydrolyzed collagen product that is FDA cleared for surgical wounds. Other collagen products require the body to naturally break down their collagen molecules, delaying the wound healing process.  CellerateRX Surgical collagen fragments are approximately 1/100^th the size of the native collagen molecule delivering the benefits of collagen immediately to the wound site.  CellerateRX Surgical can be used alone or can safely be combined with other agents, such as antibiotics, simultaneously providing broader use by the physician.  Dr. Farless said post surgery that "the incision site is the track as it's a race between healing and infection.  CellerateRX Surgical helps to win that race safely and effectively in my surgical incisions."

Patients, surgeons, and hospitals are now able to benefit from a cost effective product packaged for operating room use.

Dr. Farless also commented, "After my years of experiencing positive results with CellerateRX in the clinical environment, I am excited to extend the benefit of hydrolyzed collagen to my patients undergoing surgical procedures."

New Medicare reform guidelines are forcing physicians and hospitals to re- evaluate their surgical procedure outcomes in hopes of reducing surgical wound complications.  The proactive measure could negatively impact many hospitals as they will not be able to bill for wound healing complications after a surgery.  CellerateRX Surgical can help improve surgical outcomes by assisting in reducing surgical wound complications in patients.  The "high risk" patient having a surgical procedure can experience the utmost benefit from this product.  "High risk" patients are defined as those who are obese, elderly, a smoker, diabetic, arthritic, immune compromised or those with vascular disease.  These patients contribute to a disproportionate surgical wound complication rate of up to 10% nationally. 

"My patient's knee replacement surgery today could have cost the hospital $65,000 in post-surgical complications– a cost that will no longer be reimbursed by Medicare.  Using CellerateRX Surgical today will assist my incision site in healing and greatly reduce the risk of surgical site wound complications. This benefits everyone involved in the patients care and most importantly, the patient."

"I am really excited about this technology. CellerateRX Surgical is so easy to apply that I plan on using it in every applicable procedure. The hydrolyzed collagen gives my patients what their bodies need to repair itself in the quickest way possible," explained Dr. Farless.

Distribution of CellerateRX Surgical will be tasked to Wound Management's 255 US surgical/wound care sales representatives, all of whom are trained to facilitate CellerateRX Surgical use.

For more information or educational materials on CellerateRX or CellerateRX Surgical, please contact Wound Management Technologies (WNDM) at 1.800.205.7719 or by email at [email protected].  Wound Management Technologies website is www.wmgtech.com or you can go to its subsidiary company, Wound Care Innovations website at www.celleraterx.com.

About Wound Management Technologies, Inc.

Wound Management Technologies is a commercial stage company with current portfolio products in the $5B worldwide advanced wound care and surgical marketplaces.   The Company's focus is to facilitate global sales and distribution of cost saving advanced medical technology.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Wound Management Technologies Shareholder Information please call (800) 205-7719 or visit http://www.wmgtech.com

SOURCE Wound Management Technologies, Inc.